BURLINGTON, Mass., July 13, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2017 financial results on Thursday, July 27, 2017, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 54505762. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. Steven Chehames Investor Relations +1-781-425-1659 [email protected] http://www.lemaitre.com


Luxury Car Sales in the Middle East Take a Hit Amid Iran War
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



